Publications

Antimicrobial activity of ceftaroline tested against drug resistant subsets of Streptococcus pneumoniae from United States medical centers. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2468-2471

Zyvox® Annual Appraisal of Potency and Spectrum (ZAAPS) Program: Report of linezolid activity over 9 years (2004 – 2012). by Mendes RE, Hogan PA, Streit JM, Jones RN and Flamm RK published in J. Antimicrob. Chemother. 2014; 69 (6): 1582-1588

Ceftazidime-avibactam and comparator agents tested against urinary tract isolates from a global surveillance program (2011). by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 80 (3): 233-238

Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2274-2280

Daptomycin activity when tested against 164,457 bacterial isolates from hospitalized patients: Summary of 8 years of a worldwide surveillance programme (2005-2012). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (5): 465-469

Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States 2014. by Mendes RE, Flamm RK, Hogan PA, Ross JE and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (2): 1243-1247

Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in J. Infect. 2014; 69 (3): 266-277

Resistance surveillance program report for selected European nations (2011). by Jones RN, Flonta M, Gurler N, Cepparulo M, Mendes RE and Castanheira M published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 429-436

Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-2012). by Sader HS, Farrell DJ, Castanheira M, Flamm RK and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (10): 2713-2722

Candidemia surveillance in Iowa: emergence of echinocandin resistance. by Matsumoto E, Boyken L, Tendolkar S, McDanel J, Castanheira M, Pfaller M and Diekema D published in Diagn. Microbiol. Infect. Dis. 2014; 79 (2): 205-208

Ceftaroline activity tested against bacterial isolates from pediatric patients: Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation program for the United States (2011-2012). by Sader HS, Mendes RE, Farrell DJ, Flamm RK and Jones RN published in Pediatr. Infect. Dis. J. 2014; 33 (8): 837-842

Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (7): 3882-3888

Oritavancin activity against Staphylococcus aureus causing invasive infections in USA and European hospitals. A five-year international surveillance program. by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (5): 2921-2924

Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). by Flamm RK, Sader HS and Jones RN published in Braz. J. Infect. Dis. 2014; 18 (2): 187-195

Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: Results from the AWARE Program, 2009-2011. by Flamm RK, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 437-442

Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal, and urinary tract infections in United States medical centers (2012). by Flamm RK, Farrell DJ, Sader HS and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (6): 1589-1598

Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012). by Flamm RK, Farrell DJ, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 449-456

Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 443-448

Ceftolozane/tazobactam activity tested against gram-negative bacterial isolates from hospitalized patients with pneumonia in United States and European medical centres (2012). by Farrell DJ, Sader HS, Flamm RK and Jones RN published in Int. J. Antimicrob. Agents. 2014; 43 (6): 533-539

Antimicrobial activity of ceftazidime-avibactam against Gram-negative organisms collected from U.S. medical centers in 2012. by Sader HS, Castanheira M, Flamm RK, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (3): 1684-1692

Activity of ceftaroline and comparator agents tested against contemporary Gram-positive and -negative (2011) isolates collected in Europe, Turkey, and Israel. by Castanheira M, Jones RN and Sader HS published in J. Chemother. 2014; 26 (4): 202-210

Surveillance of antimicrobial resistance in contemporary clinical isolates of Bordetella pertussis in Ontario, Canada. by Marchand-Austin A, Memari N, Patel SN, Tang P, Deeks SL, Jamieson FB, Crowcroft NS and Farrell DJ published in Int. J. Antimicrob. Agents. 2014; 44 (1): 82-84

Frequency of occurrence and antimicrobial susceptibility of gram-negative bacteremia isolates in patients with urinary tract infection: Results from United States and European hospitals (2009-2011). by Sader HS, Flamm RK and Jones RN published in J. Chemother. 2014; 26 (3): 133-138

Spectrum and potency of ceftaroline against leading pathogens causing community-acquired respiratory tract and skin and soft tissue infections in Latin America, 2010. by Flamm RK, Sader HS and Jones RN published in Braz. J. Infect. Dis. 2013; 17 (5): 564-572

An international activity and spectrum analysis of linezolid: ZAAPS program results for 2011. by Flamm RK, Mendes RE, Ross JE, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 76 (2): 206-213

Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin or vancomycin from USA hospitals (2008–2011). by Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (7): 3178-3181

Linezolid surveillance results for the United States: LEADER Surveillance Program 2011. by Flamm RK, Mendes RE, Ross JE, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (2): 1077-1081

Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). by Sader HS, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 417-422

Activities of carbapenem and comparator agents against contemporary U.S. Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. by Morrow BJ, Pillar CM, Deane J, Sahm D, Lynch AS, Flamm RK, Peterson J and Davies TA. published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 412-416

Surveillance of dalbavancin potency and spectrum in the United States (2012). by Jones RN, Flamm RK and Sader HS published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 122-123

Antimicrobial activity of ceftaroline-avibactam tested against recent clinical isolates from USA medical centers (2010-2011). by Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (4): 1982-1988

Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). by Sader HS, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 61-68

Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). by Farrell DJ, Flamm RK, Jones RN and Sader HS published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 86-88

Spectrum and potency of ceftaroline tested against leading pathogens causing skin and soft-tissue infections in Europe (2010). by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Int. J. Antimicrob. Agents. 2013; 41 (4): 337-342

Macrolide and tetracycline resistance among Moraxella catarrhalis isolates from 2009 to 2011. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 74 (2): 198-200

Resistance trends in Gram-negative bacteria: Surveillance results from two Mexican hospitals, 2005-2010 by Morfin-Otero R, Tinoco-Favila JC, Sader HS, Salcido-Gutierrez L, Perez-Gomez HR, Gonzalez-Diaz E, Petersen L and Rodriguez-Noriega E published in BMC Res. Notes 2012; 5: 277

LEADER Surveillance program results for 2010: an activity and spectrum analysis of linezolid using 6801 clinical isolates from the United States (61 medical centers) by Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2012; 4 (1): 54-61

Multidrug resistance among Acinetobacter spp. in the USA and activity profile of key agents: Results from CAPITAL Surveillance 2010. by Queenan AM, Pillar CM, Deane J, Sahm DF, Lynch AS, Flamm RK, Peterson J and Davies TA published in Diagn. Microbiol. Infect. Dis. 2012; 73 (3): 267-270

Ceftaroline potency among 9 US census regions: Report from the 2010 AWARE program. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S194-S205

AWARE ceftaroline surveillance program (2008-2010); Trends in resistance patterns among Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States. by Pfaller MA, Farrell DJ, Sader HS and Jones RN published in Clin. Infect Dis. 2012; 55 (Suppl 3): S187-S193

Activity analyses of staphylococcal isolates from pediatric, adult and elderly patients; AWARE ceftaroline surveillance program. by Sader HS, Flamm RK, Farrell DJ and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S181-S186

In vitro activity of ceftaroline against multidrug-resistant Staphylococcus aureus and Streptococcus pneumoniae: A review of published studies and the AWARE surveillance program (2008-2010). by Farrell DJ, Castanheira M, Mendes RE, Sader HS and Jones RN published in Clin. Infect. Dis. 2012; 55 (Suppl 3): S206-S214

Oritavancin microbiologic features and activity results from the surveillance program in the United States. by Mendes RE, Farrell DJ, Sader HS and Jones RN published in Clin. Infect. Dis. 2012; 54 (Suppl 3): S203-S213

Cryptococcus neoformans-Cryptococcus gattii species complex: An international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. by Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, Govender N, Guarro J, Johnson E, Lass-Florl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, and Turnidge J published in Antimicrob. Agents Chemother. 2012; 56 (6): 3107-3113

Summary of ceftaroline activity against pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2012; 56 (6): 2933-2940

ZAAPS program results for 2010: An activity and spectrum analysis of linezolid using clinical isolates from 75 medical centres in 24 countries. by Flamm RK, Farrell DJ, Mendes RE, Ross JE, Sader HS and Jones RN published in J. Chemother. 2012; 24 (6): 328-337

Eight-year (2002-2009) summary of the linezolid (Zyvox Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries by Ross JE, Farrell DJ, Mendes RE, Sader HS, Jones RN published in J. Chem. 2011; 23 (2):71-76

Results of the Canadian Ward Surveillance Study (CANWARD) (2007-2009), a journal symposium. by Jones RN published in Diagn. Microbiol. Infect. Dis. 2011; 69 (3): 288

Antimicrobial activity of daptomycin tested against Gram-positive strains collected in European hospitals: Results from 7 years of resistance surveillance (2003-2009). by Sader HS, Farrell DJ and Jones RN published in J. Chemother. 2011; 23 (4): 200-206

Comparative activity of ceftobiprole against Gram-positive and Gram-negative isolates from Europe and the Middle East: the CLASS study. by Rossolini GM, Dryden MS, Kozlov RS, Quintana A, Flamm RK, Lauffer JM, Lee E, Morrissey I and Group CS published in J. Antimicrob Chemother. 2011; 66 (1): 151-159